Ambulance ferries liquor, belly dancers perform at govt medical college in Yogi's UP

She is one of a few beauty queens who give equal importance to both modelling and academic growth. Within months after completing her MBA in Finance and HR, Shifali Saldanha won Miss India Continent 2019 first runner-up and Miss Glory of International 2019 held in Mumbai.

An alumna of St Aloysius College (AIMIT), this 23-year-old Mangalurean is now a much sought after budding model. “I am enjoying the moment and would like to go with the flow,” says the much-loved daughter of Stephen Saldanha and late Anupama Saldanha.

Over the course of past two years, Ms Saldanha has experienced various nerve-wracking moments. She was shattered when her beloved mother lost battle with cancer and bid adieu to the world a couple of years ago. Yet, she serenely braved all the challenges. Her ‘never give up’ attitude helped her to scale new heights amidst misfortunes and pains.

Speaking to coastaldigest.com about her success in Miss India Continent 2019, which was organised by Dr Mahesh Yadav of Aman Gandhi Film Productions, Ms Saldanha said 15 contestants from different parts of the country were shortlisted for the finale, which had five diverse rounds. 

“The meet and greet session was my favourite phase in the competition as it was an opportunity to interact with the participants from different parts of the country,” recalls the multi-talented, who dreams big. 

The leggy lass’ success wasn’t accidental one. A trained singer and multilingual anchor, Ms Saldanha was already a known figure in coastal Karnataka. She had won the titles Miss Karnataka International- Multimedia 2018, and Miss Beautiful Eyes Mangaluru 2018.

Being a moderate feminist, who carries a go-getter attitude, Ms Saldanha calls upon every woman to be optimistic, challenging and goal-focused.

Bengaluru, Jan 24: After the visit of fact finding committee members to the spot, the Christian community here decided to submit a report to the state government urging to install a 114-ft. statue of Jesus Christ at Kapala Betta in Kanakapura taluk of Ramanagaram district, Congress MLC Ivan D’souza said here on Thursday.

While talking to media, Mr D’souza said the committee would submit the report to Chief Minister B.S. Yediyurappa and Revenue Minster R. Ashok and urge the government to construct the statue at the earliest.

The RSS and other BJP outfits have strongly opposed the installation, following which the government ordered suspension of the work. A few days ago, Kalladka Prabhakar, RSS ideologue, took out a rally in Kanakapura opposing the installation.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.